Click here for a message from The Motley Fool Co-Founders Tom and David Gardner. Marketing Epidiolex is about to get a lot easier for GW Pharmaceuticals. Parents of children with early-onset epilepsy and their physicians will find it easier to fill their next Epidiolex prescriptions. That’s because the CBD tincture from GW Pharmaceuticals (NASDAQ:GWPH) is…
Click On This Link for a message from The Motley Fool Co-Founders Tom and David Gardner.
Parents of children with early-onset epilepsy and their doctors will find it easier to fill their next Epidiolex prescriptions. That’s since the CBD cast from GW Pharmaceuticals( NASDAQ: GWPH) is no longer under the thumb of the Drug Enforcement Firm (DEA).
Epidiolex released in 2018 after making FDA approval as a treatment to reduce seizure frequency for patients with Lennox-Gastout syndrome and Dravet syndrome– a little population.
Image source: Getty Images.
The DEA put Epidiolex in Arrange V, the least limiting rating a drug can receive under the CSA, but there were still a lot of constraints. Efficient immediately, prescriptions for Epidiolex will be valid for an entire year and can be easily transferred in between pharmacies.
Another banner year ahead
In 2019’s fourth quarter, sales of Epidiolex reached an annualized $436 million, and sales of the CBD cast will probably climb up much further in2020 In addition to relaxed limitations, GW Pharmaceuticals might get an assisting hand from the FDA later on this year.
At the end of March, the FDA began reviewing an extra application that would broaden the drug’s addressable patient population to include patients with tuberous sclerosis complex– another serious youth illness that results in unrestrained seizures.
The FDA is expected to reveal its choice on that application on or before July 3.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>